214 related articles for article (PubMed ID: 32260165)
1. Prognostic Impact of PD-L1 Expression in Malignant Salivary Gland Tumors as Assessed by Established Scoring Criteria: Tumor Proportion Score (TPS), Combined Positivity Score (CPS), and Immune Cell (IC) Infiltrate.
Witte HM; Gebauer N; Lappöhn D; Umathum VG; Riecke A; Arndt A; Steinestel K
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32260165
[TBL] [Abstract][Full Text] [Related]
2. The expression of the adenosine pathway markers CD39 and CD73 in salivary gland carcinomas harbors the potential for novel immune checkpoint inhibition.
Bauer A; Gebauer N; Knief J; Tharun L; Arnold N; Riecke A; Steinestel K; Witte HM
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3193-3208. PubMed ID: 35902382
[TBL] [Abstract][Full Text] [Related]
3. Tumour-Infiltrating Lymphocytes (TILs) and PD-L1 Expression Correlate with Lymph Node Metastasis, High-Grade Transformation and Shorter Metastasis-Free Survival in Patients with Acinic Cell Carcinoma (AciCC) of the Salivary Glands.
Hiss S; Eckstein M; Segschneider P; Mantsopoulos K; Iro H; Hartmann A; Agaimy A; Haller F; Mueller SK
Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33669038
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic implications of immune-profiling and EGFR expression in salivary gland carcinoma.
Guazzo E; Cooper C; Wilkinson L; Feng S; King B; Simpson F; Porceddu S; Panizza B; Coward JIG
Head Neck; 2021 Mar; 43(3):768-777. PubMed ID: 33169486
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of programed death ligand-1 and ligand-2 co-expression in salivary gland carcinomas.
Nakano T; Takizawa K; Uezato A; Taguchi K; Toh S; Masuda M
Oral Oncol; 2019 Mar; 90():30-37. PubMed ID: 30846173
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 and PD-L2 Expression in Different Tumor Stages and Types of Malignant Salivary Gland Neoplasms: A Single-center Experience.
Leaf Flag B; Cam I; Civriz AH; Tunce EB; Ozcan BC; Akyol YK; Deger HM; Vural C; Ozturk M
Appl Immunohistochem Mol Morphol; 2024 Jun; ():. PubMed ID: 38847110
[TBL] [Abstract][Full Text] [Related]
7. Incidence and Prognostic Significance of PD-L1 Expression in High-Grade Salivary Gland Carcinoma.
Fang Q; Wu Y; Du W; Zhang X; Chen D
Front Oncol; 2021; 11():701181. PubMed ID: 34513680
[TBL] [Abstract][Full Text] [Related]
8. Histopathological Aspects of the Prognostic Factors for Salivary Gland Cancers.
Nishida H; Kusaba T; Kawamura K; Oyama Y; Daa T
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831578
[TBL] [Abstract][Full Text] [Related]
9. Characterisation of DOG-1 Expression in Salivary Gland Tumours and Comparison with Myoepithelial Markers.
Khurram SA; Speight PM
Head Neck Pathol; 2019 Jun; 13(2):140-148. PubMed ID: 29671211
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 expression in bladder cancer: Which scoring algorithm in what tissue?
Schulz GB; Todorova R; Braunschweig T; Rodler S; Volz Y; Eismann L; Pfitzinger P; Jokisch F; Buchner A; Stief C; Mayr D; Casuscelli J
Urol Oncol; 2021 Oct; 39(10):734.e1-734.e10. PubMed ID: 34261585
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous Expression of PD-1 and PD-L1 in Peripheral and Central Immune Cells and Tumor Cells in the Benign and Malignant Salivary Gland Tumors Microenvironment.
Gerdabi S; Asadian F; Kiani R; Khademi B; Haghshenas MR; Erfani N
Head Neck Pathol; 2023 Mar; 17(1):178-192. PubMed ID: 36169795
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact.
Locati LD; Perrone F; Cortelazzi B; Bergamini C; Bossi P; Civelli E; Morosi C; Lo Vullo S; Imbimbo M; Quattrone P; Dagrada GP; Granata R; Resteghini C; Mirabile A; Alfieri S; Orlandi E; Mariani L; Saibene G; Pilotti S; Licitra L
Eur J Cancer; 2016 Dec; 69():158-165. PubMed ID: 27821319
[TBL] [Abstract][Full Text] [Related]
13. Ki-67 and p53 immunostaining assessment of proliferative activity in salivary tumors.
Faur AC; Sas I; Motoc AG; Cornianu M; Zamfir CL; Lazăr DC; Folescu R
Rom J Morphol Embryol; 2015; 56(4):1429-39. PubMed ID: 26743291
[TBL] [Abstract][Full Text] [Related]
14. Lymphocyte activation gene 3 (LAG3) protein expression on tumor-infiltrating lymphocytes in aggressive and TP53-mutated salivary gland carcinomas.
Arolt C; Meyer M; Ruesseler V; Nachtsheim L; Wuerdemann N; Dreyer T; Gattenlöhner S; Wittekindt C; Buettner R; Quaas A; Klussmann JP
Cancer Immunol Immunother; 2020 Jul; 69(7):1363-1373. PubMed ID: 32232506
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancer.
Yamashita K; Iwatsuki M; Harada K; Eto K; Hiyoshi Y; Ishimoto T; Nagai Y; Iwagami S; Miyamoto Y; Yoshida N; Komohara Y; Ajani JA; Baba H
Gastric Cancer; 2020 Jan; 23(1):95-104. PubMed ID: 31451991
[TBL] [Abstract][Full Text] [Related]
16. Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations.
Wang K; Russell JS; McDermott JD; Elvin JA; Khaira D; Johnson A; Jennings TA; Ali SM; Murray M; Marshall C; Oldham DS; Washburn D; Wong SJ; Chmielecki J; Yelensky R; Lipson D; Miller VA; Stephens PJ; Serracino HS; Ross JS; Bowles DW
Clin Cancer Res; 2016 Dec; 22(24):6061-6068. PubMed ID: 27334835
[TBL] [Abstract][Full Text] [Related]
17. Programmed death ligand-1 expression is associated with poor disease free survival in salivary gland carcinomas.
Mukaigawa T; Hayashi R; Hashimoto K; Ugumori T; Hato N; Fujii S
J Surg Oncol; 2016 Jul; 114(1):36-43. PubMed ID: 27111278
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor (VEGF) expression and microvascular density in salivary gland tumours.
Faur AC; Lazar E; Cornianu M
APMIS; 2014 May; 122(5):418-26. PubMed ID: 23937241
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of PD-L2 is associated with shorter relapse-free survival in patients with malignant salivary gland tumors.
Chang H; Kim JS; Choi YJ; Cho JG; Woo JS; Kim A; Kim JS; Kang EJ
Onco Targets Ther; 2017; 10():2983-2992. PubMed ID: 28652780
[TBL] [Abstract][Full Text] [Related]
20. Differential expression of epidermal growth factor receptor in various pathological types of salivary gland cancers.
Fujiwara H; Kodama Y; Shimoda H; Teshima M; Shinomiya H; Nibu KI
Auris Nasus Larynx; 2024 Jun; 51(4):755-760. PubMed ID: 38852332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
